What’s on the Horizon for the Targeted Treatment of Type 2-low Asthma?
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Heart, Lung, and Blood Institute
This publication has 10 references indexed in Scilit:
- Association of Differential Mast Cell Activation with Granulocytic Inflammation in Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2022
- The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventionsJournal of Allergy and Clinical Immunology, 2021
- Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trialJournal of Allergy and Clinical Immunology, 2021
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled AsthmaNew England Journal of Medicine, 2021
- Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation FrequencyAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthmaJournal of Allergy and Clinical Immunology, 2019
- KIT Inhibition by Imatinib in Patients with Severe Refractory AsthmaNew England Journal of Medicine, 2017
- Metabolic consequences of obesity as an “outside in” mechanism of disease severity in asthmaEuropean Respiratory Journal, 2016
- Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohortsThe Lancet Respiratory Medicine, 2016
- Intraperitoneal influx of neutrophils in response to IL-33 is mast cell–dependentBlood, 2013